empasiprubart

Empasiprubart is argenx's anti-C2 antibody [1], the company's first major bet beyond FcRn blockade with efgartigimod. Phase 3 trials are running in two rare immune-mediated nerve diseases: multifocal motor neuropathy (MMN) head-to-head against IVIg [2], and chronic inflammatory demyelinating polyneuropathy (CIDP) as a placebo-controlled study [3]. The MMN trial is closest to readout, with enrollment already closed. EMA granted orphan designation in MMN in June 2025 [9].

Empasiprubart (ARGX-117) is a novel investigational monoclonal antibody, never approved anywhere. argenx is running four trials simultaneously. The most advanced is a Phase 3 head-to-head versus IVIg in MMN (NCT06742190, n=154), now active but not recruiting, which means enrollment is closed and patients are dosing through the 24-week primary endpoint window [2]. A Phase 3 in CIDP (NCT07091630, n=160) is recruiting - a 2-part design with a 24-week placebo-controlled period followed by a 96-week open-label extension [3]. A Phase 2 study in generalized myasthenia gravis as add-on to efgartigimod (NCT07284420, n=70) just opened [4], hedging empasiprubart as combination therapy in the indication that built argenx. A Phase 1 study (NCT07612020) is testing subcutaneous autoinjector bioavailability against IV [5]: argenx is already preparing the SC format that turned efgartigimod into a multi-billion-dollar franchise. Phase 1 results were published in Nature Communications in 2025 [1], showing safe and sustained inhibition of both classical and lectin complement pathways in healthy volunteers, with no major safety signals through the dosing period. EMA granted orphan designation for MMN on 2025-06-20 (EU/3/25/3070) [9]. No FDA breakthrough therapy, fast track, or orphan designations have been publicly disclosed. Expected readout for the MMN Phase 3 primary endpoint is likely late 2026 to early 2027, given the week-24 timing and closed enrollment.

The complement system is a cascade of about 30 proteins that punches holes in pathogens and tags them for destruction by immune cells. It runs through three entry routes: classical (triggered by antibody-antigen complexes), lectin (sugar patterns on microbes), and alternative (constant low-level surveillance). C2 sits at the choke point of the classical and lectin pathways. Block it and immune-complex-driven inflammation stops, but alternative pathway antimicrobial defense stays intact. That selectivity is the pitch versus C5 blockers like eculizumab, which shut down the whole cascade and require meningococcal vaccination before dosing. In MMN and CIDP, autoantibodies bind peripheral nerve targets (anti-GM1 ganglioside in MMN, various myelin antigens in CIDP) and engage the classical pathway through C1q. That recruits C2, drives C3/C5 convertase formation, and ultimately damages the nerve sheath or motor axons. Blocking C2 severs the link between antibody binding and complement-mediated nerve damage without touching antibody levels themselves, which is the mechanistic distinction from efgartigimod. (FcRn is a protein that recycles antibodies; blocking it accelerates IgG degradation, lowering pathogenic autoantibody levels - efgartigimod's mechanism.) Complement deposition is documented in nerve biopsies from both diseases, and the classical pathway is the dominant route to damage. Whether the clinical signal will be large enough versus IVIg, itself a partial complement modulator among other actions, is the open question.

The MMN Phase 3 (NCT06742190) is the readout to watch [2]. Head-to-head versus IVIg, n=154, primary endpoint is change from baseline in grip strength (4-week average) in the most affected hand at week 24. ACTIVE_NOT_RECRUITING means enrollment is closed. A head-to-head against IVIg is bold. IVIg works in MMN, that is why it is standard, and grip strength is a noisy endpoint in a heterogeneous patient population. argenx is likely playing for non-inferiority with a cleaner dosing profile: no monthly multi-hour infusions, no plasma-supply constraints, no surge demand during IVIg shortages. The risk is that a draw on efficacy does not sell itself to neurologists who already trust IVIg. The CIDP Phase 3 (NCT07091630) is placebo-controlled, not head-to-head against efgartigimod, with a 24-week double-blind RCT (Part A) followed by a 96-week open-label extension (Part B) [3]. Primary endpoint is ≥1 point reduction at week 24 on aINCAT (a validated physician-rated disability score for inflammatory neuropathies, scored 0-10). n=160. Standard endpoint, standard design. The placebo comparator means argenx is testing pure efficacy, not differentiation from its own efgartigimod (approved in CIDP in 2024); the commercial fight against efgartigimod is implicit in the strategy but not encoded in the trial. The Phase 2 ARDA MMN study (NCT05225675, n≈54 across two sequential cohorts) was a randomized, double-blind, placebo-controlled trial whose primary endpoint was safety and tolerability - which was met [6][7]. argenx has reported exploratory efficacy at PNS 2024: a 91% reduction in the risk of IVIg retreatment versus placebo, with improvements in grip strength and patient-reported disability [7]. The Phase 2 was not powered for a confirmatory grip-strength readout, so the Phase 3 head-to-head still carries genuine endpoint risk.

The model gives this drug an 18% chance of eventually being approved. That figure starts from a historical baseline of about 61% for Phase 3 drugs in this area, then adjusts based on ten facts about the trial and its sponsor. The estimate is pulled upward by more secondary endpoints than usual, and pulled downward by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak earlier-phase results. The remaining factors fall close to average and leave the number roughly where the baseline placed it.

Efficacy: MMN is the harder problem. Grip strength can swing for non-disease reasons, and the Phase 2 was not powered for a grip-strength primary. The 91% IVIg-retreatment reduction is encouraging but does not directly translate to the Phase 3 primary, and a numerically inferior grip-strength result against IVIg - even with cleaner dosing - would make the label fight ugly. Comparable autoimmune programs at argenx have failed at Phase 3 (efgartigimod missed in pemphigus and primary immune thrombocytopenia in 2023), demonstrating that even mechanistically sound programs can miss confirmatory endpoints. Safety: blocking the classical pathway raises infection risk, particularly with encapsulated bacteria (pneumonia, less meningococcal risk than C5 blockers but not zero). The Phase 1 paper [1] reported tolerability through three months in healthy volunteers. Chronic dosing safety in older neuropathy patients on background immunosuppression is the open question, and is exactly the population that will use this drug commercially. Execution: argenx is running four empasiprubart trials simultaneously across three indications. Cannibalization risk with their own efgartigimod in CIDP is real, and physicians may default to the approved drug. The gMG add-on study (NCT07284420) is telling: argenx is positioning empasiprubart as combination therapy with efgartigimod, not as a replacement [4]. Commercial: IVIg costs $5,000-$10,000 per infusion, monthly, for years. Empasiprubart will need to price competitively while justifying the switch. CIDP patients stable on efgartigimod will not switch absent a clear benefit, and a placebo-controlled Phase 3 does not generate the head-to-head data payers will want.

Worth watching, but not the highest-conviction argenx pipeline asset. The MMN Phase 3 readout is the key data point: with US MMN diagnosed prevalence around 3,000-10,000 patients (1-5 per 100,000) and an anchor ASP at parity with current IVIg cost-of-care ($60-180K/year per patient), the US market ceiling at 50% penetration over five years is roughly $250-500M; global doubling brings the addressable opportunity to $500M-$1B - defensible as an upside scenario, contingent on a label that supports IVIg switching. Superiority on grip strength would change the standard of care and push the upper bound. A miss on the primary endpoint forces a regroup but does not kill the CIDP and gMG programs, which are mechanistically and operationally decoupled. The EMA orphan designation in MMN [9] secures 10 years of EU market exclusivity if approved - material for the European commercial timeline. The composition-of-matter patent expiry has not been publicly disclosed by argenx; the molecule is a 2017-era discovery, so a 2037-2040 patent horizon is the rough expectation, with biosimilar risk pushed beyond the first decade post-approval. The real strategic signal is what empasiprubart does for argenx's identity. argenx pulled in $4.2B in trailing revenue [8], almost all from efgartigimod (Vyvgart/Vyvgart Hytrulo). One drug, one mechanism, one franchise risk. If empasiprubart works, argenx becomes a two-mechanism immunology company (FcRn blockade plus classical complement inhibition), which is a re-rating event for the stock and de-risks the long-term R&D thesis. If it fails, the FcRn concentration risk gets sharper. Check back: late 2026 for the MMN Phase 3 topline. In the interim, watch for SC autoinjector PK data from NCT07612020 [5] and any further conference presentation of Phase 2 ARDA grip-strength detail [7].